SG11202008433QA - Compounds including a mutant kras sequence and a lipid and uses thereof - Google Patents
Compounds including a mutant kras sequence and a lipid and uses thereofInfo
- Publication number
- SG11202008433QA SG11202008433QA SG11202008433QA SG11202008433QA SG11202008433QA SG 11202008433Q A SG11202008433Q A SG 11202008433QA SG 11202008433Q A SG11202008433Q A SG 11202008433QA SG 11202008433Q A SG11202008433Q A SG 11202008433QA SG 11202008433Q A SG11202008433Q A SG 11202008433QA
- Authority
- SG
- Singapore
- Prior art keywords
- lipid
- compounds including
- mutant kras
- kras sequence
- sequence
- Prior art date
Links
- 101150105104 Kras gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
- C12Y306/05002—Small monomeric GTPase (3.6.5.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862637879P | 2018-03-02 | 2018-03-02 | |
PCT/US2019/020404 WO2019169332A1 (en) | 2018-03-02 | 2019-03-01 | Compounds including a mutant kras sequence and a lipid and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202008433QA true SG11202008433QA (en) | 2020-09-29 |
Family
ID=67805548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008433QA SG11202008433QA (en) | 2018-03-02 | 2019-03-01 | Compounds including a mutant kras sequence and a lipid and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210060149A1 (zh) |
EP (1) | EP3758713A4 (zh) |
JP (2) | JP7419268B2 (zh) |
KR (1) | KR20200141994A (zh) |
CN (1) | CN112118847B (zh) |
AU (1) | AU2019226586A1 (zh) |
BR (1) | BR112020017645A2 (zh) |
CA (1) | CA3092679A1 (zh) |
IL (1) | IL277100A (zh) |
MA (1) | MA52435A (zh) |
MX (1) | MX2020009149A (zh) |
SG (1) | SG11202008433QA (zh) |
WO (1) | WO2019169332A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116867799A (zh) * | 2021-02-10 | 2023-10-10 | 上海吉倍生物技术有限公司 | Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体 |
KR20230068628A (ko) | 2021-11-11 | 2023-05-18 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
KR20230068627A (ko) | 2021-11-11 | 2023-05-18 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법 |
KR20230101284A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101283A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101287A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101286A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101285A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
GB9103974D0 (en) * | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7709002B1 (en) * | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
EP0895538B1 (en) * | 1996-04-19 | 2002-07-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes |
US20050170457A1 (en) * | 2003-12-31 | 2005-08-04 | Chadler Pool | Novel recombinant proteins with N-terminal free thiol |
AU2012209274A1 (en) * | 2011-01-24 | 2013-09-12 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
KR20150006477A (ko) * | 2012-05-09 | 2015-01-16 | 그래댈리스, 인코포레이티드 | 단일-뉴클레오타이드 kras 돌연변이에 특이적인 이-기능성 짧은-헤어핀 rna (bi-shrna) |
CN104471062A (zh) * | 2012-07-16 | 2015-03-25 | 协和发酵麒麟株式会社 | 抑制KRAS基因表达的RNAi医药组合物 |
CN107847505A (zh) * | 2014-09-11 | 2018-03-27 | 威登卓制药公司 | 多层脂质囊泡组合物及使用方法 |
EP3405576A4 (en) * | 2016-01-19 | 2019-09-18 | The University of North Carolina at Chapel Hill | METHODS AND COMPOSITIONS USING RNA INTERFERENCE FOR KRAS INHIBITION |
SG11201901979SA (en) * | 2016-11-30 | 2019-04-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
US20190048049A1 (en) * | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding Sa | Cargomers |
-
2019
- 2019-03-01 AU AU2019226586A patent/AU2019226586A1/en active Pending
- 2019-03-01 MX MX2020009149A patent/MX2020009149A/es unknown
- 2019-03-01 BR BR112020017645-1A patent/BR112020017645A2/pt unknown
- 2019-03-01 CN CN201980028790.5A patent/CN112118847B/zh active Active
- 2019-03-01 KR KR1020207028273A patent/KR20200141994A/ko not_active Application Discontinuation
- 2019-03-01 CA CA3092679A patent/CA3092679A1/en active Pending
- 2019-03-01 US US16/977,155 patent/US20210060149A1/en active Pending
- 2019-03-01 SG SG11202008433QA patent/SG11202008433QA/en unknown
- 2019-03-01 EP EP19761691.5A patent/EP3758713A4/en active Pending
- 2019-03-01 JP JP2020568946A patent/JP7419268B2/ja active Active
- 2019-03-01 WO PCT/US2019/020404 patent/WO2019169332A1/en active Application Filing
- 2019-03-01 MA MA052435A patent/MA52435A/fr unknown
-
2020
- 2020-09-02 IL IL277100A patent/IL277100A/en unknown
-
2024
- 2024-01-10 JP JP2024001725A patent/JP2024050594A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3758713A1 (en) | 2021-01-06 |
AU2019226586A1 (en) | 2020-10-15 |
WO2019169332A1 (en) | 2019-09-06 |
KR20200141994A (ko) | 2020-12-21 |
JP2024050594A (ja) | 2024-04-10 |
CN112118847B (zh) | 2024-05-28 |
BR112020017645A2 (pt) | 2020-12-29 |
CA3092679A1 (en) | 2019-09-06 |
US20210060149A1 (en) | 2021-03-04 |
IL277100A (en) | 2020-10-29 |
JP7419268B2 (ja) | 2024-01-22 |
CN112118847A (zh) | 2020-12-22 |
MA52435A (fr) | 2021-01-06 |
EP3758713A4 (en) | 2021-12-29 |
MX2020009149A (es) | 2021-01-15 |
RU2020132290A (ru) | 2022-04-05 |
JP2021517471A (ja) | 2021-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277100A (en) | Compounds Containing a Mutant KRAS Sequence and a Lipid and Uses Therefor | |
IL261175A (en) | Methods and compounds for restoring mutant p53 activity | |
IL291593A (en) | Methods and compositions for restoring mutant p53 function | |
PT3720442T (pt) | Inibição de idh-1 mutante | |
IL279153A (en) | Mutant CPF1 endonucleases | |
EP3733689A4 (en) | TRANSAMINASE MUTANT AND APPLICATION OF IT | |
EP3805381A4 (en) | MUTATED PHYTASE | |
EP3747788A4 (en) | FASTENERS | |
EP3806844A4 (en) | DOTA COMPOUNDS AND USES THEREOF | |
GB201903827D0 (en) | New compounds and methods | |
GB201812992D0 (en) | Liposomes | |
EP3677674A4 (en) | TRANSAMINASE MUTANT AND ITS USE | |
EP3712262A4 (en) | MUTANT TRANSAMINASE AND ASSOCIATED APPLICATION | |
EP4050100A4 (en) | TRANSAMINASE MUTANT AND USE THEREOF | |
GB201903832D0 (en) | New compounds and methods | |
IL281510A (en) | Push chair | |
GB201913110D0 (en) | New compounds and methods | |
GB201903854D0 (en) | Pillow | |
EP3697806A4 (en) | TUBERCULOSIS ANTIGEN CASSETTES | |
LT3720442T (lt) | Mutantinės idh-1 slopinimas | |
CA187398S (en) | Pillow | |
CA194814S (en) | Pillow | |
CA187541S (en) | Zipper | |
GB201908955D0 (en) | Button development 05 | |
GB201908608D0 (en) | Button development 04 |